ArticleNature2020
Potently neutralizing and protective human antibodies against SARS-CoV-2.
Open access · bronzeAbstract read
In one paragraph
Article in Nature, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 758 papers.
0numbers the graph read from it
0cells of the map it votes in
758citing papers in PubMed
25.8field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
758 citing papers in PubMed, 1,186 citations in OpenAlex.
- Safety, tolerability, and pharmacokinetics of anti-SARS-CoV-2 monoclonal antibody SA55 injection in healthy participants.Antimicrobial agents and chemotherapy · 2025Trial
- Breakthrough SARS-CoV-2 Infections in the PROVENT Prevention Trial Were Not Associated With AZD7442 (Tixagevimab/Cilgavimab) Resistant Variants.The Journal of infectious diseases · 2023Trial
- Safety, Tolerability and Pharmacokinetics of Half-Life Extended Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Monoclonal Antibodies AZD7442 (Tixagevimab-Cilgavimab) in Healthy Adults.The Journal of infectious diseases · 2023Trial
- AZD7442 (Tixagevimab/Cilgavimab) for Post-Exposure Prophylaxis of Symptomatic Coronavirus Disease 2019.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023Trial
- Deep mutational scanning reveals the antibody escape and infectivity landscape of SARS-CoV-2 Omicron JN.1 and XEC receptor-binding domains.Emerging microbes & infections · 2026Article
- Safety, Pharmacokinetics, and Predicted Neutralizing Activity of the SARS-CoV-2 Monoclonal Antibody Sipavibart: Results from Little DIPPER and the SUPERNOVA Substudy.Infectious diseases and therapy · 2026Article
- Exposure route, not dose, is the primary driver of infection patterns for a respiratory virus.Science advances · 2026Article
- Article
- ACE2-like Catalytic Activity in Anti-SARS-CoV-2 Spike Protein Monoclonal Antibodies.Pathogens (Basel, Switzerland) · 2026Article
- Rapid discovery of monoclonal antibodies via high-throughput single BCR affinity sequencing.Nucleic acids research · 2026Article
- Structural and functional characterization of a conserved cryptic epitope on SARS-CoV-2 spike S2 subunit.PLoS pathogens · 2026Article
- Structure-Guided Design of Therapeutic Antibodies Targeting SARS-CoV-2 Omicron Variants.Research square · 2026Article
- Human angiotensin‑converting enzyme 2‑specific benzothiazole-based allosteric inhibitor against pan‑sarbecoviruses.Nature communications · 2026Article
- Antibody Transcytosis and Neutralizing Activity in Respiratory Epithelial Cells.bioRxiv : the preprint server for biology · 2026Article
- Article
- Building better antibody responses: The interplay of infection, vaccination, and immune imprinting.PNAS nexus · 2026Review
- Epitope-focused discovery of SARS-CoV-2 antibodies that potently neutralize Omicron variants.Nature microbiology · 2026Article
- Monoclonal antibodies from COVID-19 convalescent patients target cryptic epitopes for broad SARS-CoV-2 neutralization.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Evaluating southern pigtail macaques as an immunological model for human antibody responses.Scientific reports · 2026Article
- Mining antibody functionality via AI-guided structural landscape profiling.Nature communications · 2026Article
698 more citing papers are in PubMed but not listed here.
Corrections and comments
- Update of
Authors and funding
41 authors at 6 institutions in 2 countries.
Seth J Zost *Vanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN, USA.ORCID http://orcid.org/0000-0001-6712-5076
Pavlo Gilchuk *Vanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN, USA.
James Brett CaseDepartment of Medicine, Washington University School of Medicine, St Louis, MO, USA.ORCID http://orcid.org/0000-0001-7331-5511
Elad BinshteinVanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN, USA.ORCID http://orcid.org/0000-0003-2745-104X
Rita E ChenDepartment of Medicine, Washington University School of Medicine, St Louis, MO, USA.
Joseph P NkololaCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
Alexandra SchäferDepartment of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Joseph X ReidyVanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN, USA.
Andrew TrivetteVanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN, USA.
Rachel S NargiVanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN, USA.
Rachel E SuttonVanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN, USA.
Naveenchandra SuryadevaraVanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN, USA.
David R MartinezDepartment of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Lauren E WilliamsonDepartment of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, TN, USA.
Elaine C ChenDepartment of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, TN, USA.ORCID http://orcid.org/0000-0001-7883-8039
Taylor JonesVanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN, USA.
Samuel DayVanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN, USA.
Luke MyersVanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN, USA.
Ahmed O HassanDepartment of Medicine, Washington University School of Medicine, St Louis, MO, USA.
Natasha M KafaiDepartment of Medicine, Washington University School of Medicine, St Louis, MO, USA.ORCID http://orcid.org/0000-0002-3115-3400
Emma S WinklerDepartment of Medicine, Washington University School of Medicine, St Louis, MO, USA.
Julie M FoxDepartment of Medicine, Washington University School of Medicine, St Louis, MO, USA.
Swathi ShrihariDepartment of Medicine, Washington University School of Medicine, St Louis, MO, USA.
Benjamin K MuellerDepartment of Chemistry, Vanderbilt University, Nashville, TN, USA.
Jens MeilerDepartment of Chemistry, Vanderbilt University, Nashville, TN, USA.ORCID http://orcid.org/0000-0001-8945-193X
Abishek ChandrashekarCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0001-7821-5552
Noe B MercadoCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0001-7769-7326
James J SteinhardtAntibody Discovery and Protein Engineering, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA.ORCID http://orcid.org/0000-0001-9662-9994
Kuishu RenMicrobial Sciences, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA.
Yueh-Ming LooMicrobial Sciences, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA.
Nicole L KallewaardMicrobial Sciences, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA.
Broc T McCuneDepartment of Medicine, Washington University School of Medicine, St Louis, MO, USA.
Shamus P KeelerDepartment of Medicine, Washington University School of Medicine, St Louis, MO, USA.
Michael J HoltzmanDepartment of Medicine, Washington University School of Medicine, St Louis, MO, USA.
Dan H BarouchCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
Lisa E GralinskiDepartment of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Ralph S BaricDepartment of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Larissa B ThackrayDepartment of Medicine, Washington University School of Medicine, St Louis, MO, USA.ORCID http://orcid.org/0000-0002-9380-6569
Michael S DiamondDepartment of Medicine, Washington University School of Medicine, St Louis, MO, USA.
Robert H CarnahanVanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN, USA. Robert.carnahan@vumc.org.ORCID http://orcid.org/0000-0001-5230-1532
James E CroweVanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN, USA. james.crowe@vumc.org.ORCID http://orcid.org/0000-0002-0049-1079
Vanderbilt University Medical Center · USWashington University in St. Louis · USAstraZeneca (United States) · USBeth Israel Deaconess Medical Center · USUniversity of North Carolina at Chapel Hill · USVanderbilt University · US
Funding
Vanderbilt Institute for Clinical and Translational Research (VICTR) -Identifying correlates of functional immunity in SARS-CoV-2 convalescent plasmaUL1TR002243 · NCATS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Paul A. Harris, Wesley H Self · 2017 to 2026
$130.7MTRAINING PROGRAM IN IMMUNOLOGY AND IMMUNOGENETICST32AI007163 · NIAID · WASHINGTON UNIVERSITY · PI Kenneth M Murphy, Kodi S Ravichandran · 1985 to 2026
$14.8MCOVID Supplement B Cell Epitope Discovery and Mechanisms of Antibody Protection.75N93019C00062 · NIAID · WASHINGTON UNIVERSITY · PI FREMONT, DAVED · 2019 to 2023
$11.7MB-CELL EPITOPE DISCOVERY AND MECHANISMS OF ANTIBODY PROTECTION: Modification for SARS-CoV2 Research75N93019C00074 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI CROWE, JAMES E · 2019 to 2024
$10.2MDefining and Controlling Airway DiseaseR35HL145242 · NHLBI · WASHINGTON UNIVERSITY · PI HOLTZMAN, MICHAEL J · 2019 to 2025
$6.6MStructure based design of trimer interface epitope focused universal influenza vaccinesU01AI150739 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI CROWE, JAMES E · 2020 to 2024
$6.1MHuman antibody-based countermeasures against the Wuhan Coronavirus SARS-CoV-2R01AI157155 · NIAID · WASHINGTON UNIVERSITY · PI BARIC, RALPH S, CROWE, JAMES E · 2020 to 2024
$6.0MINFECTIOUS DISEASE PATHOGENESIS TRAININGT32AI007151 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI JULIANO, JONATHAN J · 1985 to 2024
$5.5MChildhood Infections Research ProgramT32AI095202 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI JAMES E CASSAT · 2011 to 2026
$4.2MPARP9-DTX3L Control Of Viral Infection and Airway DiseaseR01AI130591 · NIAID · WASHINGTON UNIVERSITY · PI HOLTZMAN, MICHAEL J · 2017 to 2021
$3.0MImmunological Mechanisms of Disease Training ProgramT32AI138932 · NIAID · VANDERBILT UNIVERSITY · PI MAJOR, AMY S, RATHMELL, JEFFREY C. · 2019 to 2023
$1.4MIllumina Genome Analyzer IIS10RR028106 · NCRR · VANDERBILT UNIVERSITY · PI GEORGE, ALFRED L. · 2011 to 2011
$515kNCATS NIH HHS UL1 TR002243NCRR NIH HHS S10 RR028106NHLBI NIH HHS R35 HL145242NIAID NIH HHS 75N93019C00062NIAID NIH HHS 75N93019C00074NIAID NIH HHS F30 AI152327NIAID NIH HHS F31 AI145189NIAID NIH HHS F32 AI138392NIAID NIH HHS R01 AI130591NIAID NIH HHS R01 AI157155NIAID NIH HHS T32 AI007151NIAID NIH HHS T32 AI007163NIAID NIH HHS T32 AI095202NIAID NIH HHS T32 AI138932NIAID NIH HHS U01 AI150739Wellcome Trust
Abstract
The ongoing pandemic of coronavirus disease 2019 (COVID-19), which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is a major threat to global health
Indexed as
Angiotensin-Converting Enzyme 2AnimalsAntibodies, MonoclonalAntibodies, NeutralizingAntibodies, ViralBetacoronavirusBinding, CompetitiveCell LineCoronavirus InfectionsCOVID-19Cross ReactionsDisease Models, AnimalEpitopes, B-LymphocyteFemaleHumansMacaca mulattaACE2 protein, humanAce2 protein, mouseAngiotensin-Converting Enzyme 2Antibodies, MonoclonalAntibodies, NeutralizingAntibodies, ViralEpitopes, B-LymphocytePeptidyl-Dipeptidase ASpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.